Compare ONC & PRU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ONC | PRU |
|---|---|---|
| Founded | 2010 | 1875 |
| Country | Switzerland | United States |
| Employees | 12000 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Life Insurance |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.6B | 42.4B |
| IPO Year | 2015 | 2001 |
| Metric | ONC | PRU |
|---|---|---|
| Price | $346.33 | $118.84 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 15 |
| Target Price | ★ $385.10 | $103.71 |
| AVG Volume (30 Days) | 280.6K | ★ 1.5M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 5.81% |
| EPS Growth | ★ 140.43 | 33.20 |
| EPS | 0.31 | ★ 4.48 |
| Revenue | $238,387,000.00 | ★ $60,774,000,000.00 |
| Revenue This Year | $723.76 | N/A |
| Revenue Next Year | $15.04 | $3.06 |
| P/E Ratio | $1,132.26 | ★ $26.25 |
| Revenue Growth | ★ 22179.16 | N/A |
| 52 Week Low | $253.95 | $91.89 |
| 52 Week High | $385.22 | $127.72 |
| Indicator | ONC | PRU |
|---|---|---|
| Relative Strength Index (RSI) | 43.73 | 45.66 |
| Support Level | $327.01 | $117.12 |
| Resistance Level | $353.10 | $119.04 |
| Average True Range (ATR) | 7.21 | 2.33 |
| MACD | -4.61 | -0.46 |
| Stochastic Oscillator | 18.95 | 27.00 |
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Prudential Financial is one of the largest US life insurers, offering annuities, life insurance, and asset-management products. The United States and Japan are its two largest markets. Its US business contributed about 50% of adjusted 2025 earnings and includes institutional retirement (mostly pension risk transfer), individual retirement (annuities), group insurance, and individual life insurance. Its international business represented about 39% of adjusted earnings, with a strong market position in Japan, and the firm also has a presence in emerging markets like Brazil. The company's investment management business, PGIM, contributed approximately 11% of its 2025 adjusted earnings. PGIM had around $1.47 trillion in assets under management at the end of fourth-quarter 2025.